Company news

Veracyte, Inc. news in 2024

Veracyte, Inc.'s news releases, calls and decks from 2024, newest first.

View company

Veracyte’s Decipher Prostate Test Is Now the Only Gene Expression Test Recommended in NCCN® Prostate Cancer Guidelines

December 4, 2024

Veracyte Announces Third Quarter 2024 Financial Results

November 5, 2024

Veracyte to Release Third Quarter 2024 Financial Results on November 6, 2024

October 15, 2024

New Data Presented at ASTRO 2024 Show that Veracyte’s Decipher Prostate Test Predicts Aggressive Prostate Cancer in African American Men

October 1, 2024

New Data Presented at ESMO 2024 Show that Veracyte’s Decipher Prostate Test Predicts Chemotherapy Benefit in Patients with Metastatic Prostate Cancer

September 14, 2024

Veracyte Appoints Brent Shafer and Tom Miller, Ph.D., to Its Board of Directors

September 3, 2024

Veracyte to Participate in the Morgan Stanley 22nd Annual Global Healthcare Conference

August 25, 2024

Veracyte Named a Greater Bay Area Top Workplace by the San Francisco Chronicle

August 25, 2024

Veracyte Announces Second Quarter 2024 Financial Results

August 5, 2024

Veracyte to Release Second Quarter 2024 Financial Results on August 6, 2024

July 16, 2024

Veracyte Announces that New Afirma GRID Data Suggest Prognostic Ability of Molecular Testing for Thyroid Tumors

June 2, 2024

Veracyte Announces Multiple Afirma GRID Presentations at ENDO 2024, Previewing the Future of Molecular Testing in Thyroid Nodules and Cancer

May 21, 2024

Veracyte Announces First Quarter 2024 Financial Results

May 6, 2024

14 Studies Presented at AUA 2024 Show Decipher Tests’ Ability to Help Personalize Care for Prostate and Bladder Cancer Patients and Advance Disease Understanding

May 5, 2024

Veracyte to Release First Quarter 2024 Financial Results on May 7, 2024

April 21, 2024

New Study Shows Veracyte’s Decipher Prostate Test is Prognostic for Prostate Cancer Progression Among Patients Undergoing Active Surveillance

April 21, 2024

Veracyte Announces that Nine Studies Reinforcing the Value of Decipher Prostate and Decipher Bladder Testing Will Be Presented at AUA 2024

April 15, 2024

Veracyte’s Decipher Prostate Test Receives Highest Evidence-Level Rating Among Molecular Tests in Updated Prostate Cancer NCCN Guidelines

February 26, 2024

Veracyte Announces Fourth Quarter and Full-Year 2023 Financial Results

February 21, 2024

Veracyte to Participate in the Raymond James 45th Annual Institutional Investors Conference

February 20, 2024

Veracyte to Release Fourth Quarter and Full-Year 2023 Financial Results on February 22, 2024

February 7, 2024

Veracyte Completes Acquisition of C2i Genomics

February 5, 2024

Veracyte Announces Preliminary Full-Year 2023 Results, Acquisition of C2i Genomics to Add Minimal Residual Disease Capabilities to Its Novel Diagnostics Platform

January 7, 2024

Calls in 2024

Decks in 2024